Tesaro, Inc. (Waltham, Massachusetts)
309 Waverley Oaks Road
230 articles with Tesaro, Inc. (Waltham, Massachusetts)
TESARO, Inc. will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets.
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
TESARO, Inc. today announced that data from six abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.
TESARO, Inc. today announced that data from a total of five abstracts will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 7-11, 2018 in Washington, D.C.
9/25/2018Ovarian cancer is the fifth leading cause of cancer-related deaths in the United States. It is estimated that this year there will be more than 22,000 women in the U.S. diagnosed with the disease and about 14,000 disease-related deaths.
Tesaro, Inc., an oncology-focused biopharmaceutical company, announced its participation in two upcoming investor conferences.
TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer
All evaluable patients experienced tumor shrinkage
TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
TESARO, Inc. will announce first-quarter 2018 financial results onThursday, May 3, 2018, after the close of the U.S. financial markets.
CancerCare®, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, announced that TESARO will receive their 2018 Partnership Award.
The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable.
With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference.
In clinical trials, the most common adverse reactions reported were neutropenia, hiccups, decreased appetite and dizziness.
1/15/2018Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.
TESARO Announces Availability of ZEJULA (niraparib) for Women With Recurrent Ovarian Cancer in Germany
ZEJULA is the first once-daily, oral PARP inhibitor to be approved in Europe that does not require BRCA mutation or biomarker testing.
TESARO Announces Availability of VARUBI (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
The U.S. Food and Drug Administration (FDA) approved VARUBI injectable emulsion on October 25, 2017.
The loan facility provides TESARO with up to $500 million of borrowing capacity available in two tranches.